What Are Chemotherapy-Induced Nausea and Vomiting?
Chemotherapy-induced nausea and vomiting (CINV) are frequent and debilitating side effects of antineoplastic agents. Despite advances in antiemetics, CINV continues to be ranked by oncology patients as one of the most feared side effects, significantly affecting quality of life.
Incidence depends on the emetogenic potential of the chemotherapy used. Highly emetogenic agents such as cisplatin cause CINV in more than 90% of patients without adequate prophylaxis. Even with modern prophylaxis, 30-40% of patients still experience some nausea.
Uncontrolled CINV can lead to dehydration, malnutrition, dose reduction, or delays in chemotherapy cycles — potentially compromising cancer treatment efficacy. Adequate CINV control is therefore essential for therapeutic success.
Most Feared Side Effect
Patients consistently rank CINV as the most distressing side effect of chemotherapy, often above fatigue and alopecia.
Three Phases
CINV is classified into acute (0-24h), delayed (24h-5 days), and anticipatory (before infusion), each with distinct mechanisms and treatments.
Prevention Is Possible
Modern antiemetic protocols control CINV in 70-90% of patients. Prevention is more effective than rescue treatment.
Pathophysiology
CINV involves two main pathways. The peripheral pathway is activated when chemotherapy agents damage enterochromaffin cells in the small intestine, releasing serotonin (5-HT) that activates 5-HT3 receptors on vagal afferents, transmitting the emetic signal to the brainstem.
The central pathway involves direct activation of the chemoreceptor trigger zone (area postrema) by chemotherapy metabolites in circulation, where neurokinin NK1, dopaminergic D2, and serotonergic receptors are stimulated. Substance P, acting on NK1 receptors, is the main mediator of delayed emesis.
CINV PHASES AND MECHANISMS
| PHASE | TIME | MAIN MEDIATOR | KEY TREATMENT |
|---|---|---|---|
| Acute | 0-24 hours | Serotonin (5-HT3) | 5-HT3 antagonists (ondansetron) |
| Delayed | 24h to 5 days | Substance P (NK1) | NK1 antagonists (aprepitant) |
| Anticipatory | Before infusion | Classical conditioning | Benzodiazepines, CBT |
Symptoms
CINV's clinical presentation varies by phase and by the chemotherapy regimen's emetogenic potential. Delayed nausea — occurring 24 hours to 5 days after infusion — is often more difficult to control than acute nausea.
CINV Manifestations
- 01
Acute nausea
Occurs in the first 24 hours. Peaks in intensity 5-6 hours after infusion. Mediated mainly by serotonin.
- 02
Delayed nausea
Begins after 24 hours and may persist for 5-7 days. More refractory to treatment and frequently underestimated.
- 03
Anticipatory nausea
Occurs before infusion in patients with poorly controlled CINV in previous cycles. It is a conditioned (Pavlovian) response.
- 04
Associated anorexia
Loss of appetite that accompanies nausea, potentially causing significant weight loss across cycles.
- 05
Dehydration
Repeated vomiting can cause dehydration, electrolyte imbalance, and the need for intravenous hydration.
- 06
Psychological impact
Anticipatory anxiety, fear of treatment, and reduced adherence to chemotherapy.
Classification and Assessment
Assessment of CINV is based on classification of the emetogenic potential of the chemotherapy regimen and patient risk factors. Factors that increase risk include female sex, younger age, history of motion sickness, CINV in previous cycles, and low alcohol consumption.
CINV severity is assessed by standardized scales such as the visual analog nausea scale, the vomiting diary, and disease-specific quality of life questionnaires (FLIE — Functional Living Index-Emesis).
DIAGNÓSTICO DIFERENCIAL
Differential Diagnosis
Anticipatory vs Acute vs Delayed CINV
- Anticipatory: before chemo; acute: 24h; delayed: 2-5 days
Testes Diagnósticos
- Temporal clinical assessment
Tumor-Related Bowel Obstruction
- Nausea + vomiting + cessation of flatus
- Tumor progression
- Abdominal distention
- Tumor obstruction = surgical oncology evaluation
Testes Diagnósticos
- Abdominal CT
Tumor-Related Hypercalcemia
- Nausea + polyuria + confusion + weakness
- Elevated calcium
- Myeloma, bone metastasis
- Severe hypercalcemia = urgent IV hydration
Testes Diagnósticos
- Serum calcium
- PTH-rP
Esophageal Mucositis
- Pain on swallowing associated with chemo/radiation
- Dysphagia for solids
- No predominant nausea
Testes Diagnósticos
- Endoscopy if necessary
Carcinomatous Meningitis
- Nausea + headache + neck stiffness in oncology patient
- Insidious progression
- Abnormal CSF
- Carcinomatous meningitis = neuro-oncology evaluation
Testes Diagnósticos
- CSF
- MRI with gadolinium
CINV Phases: Anticipatory, Acute, and Delayed
CINV is divided into three phases with distinct mechanisms. Anticipatory nausea occurs before chemotherapy infusion — through classical conditioning, in which stimuli associated with the oncology environment (smells, colors, voices) trigger the nausea response. It is more common in patients with poor control in previous cycles, elevated anxiety, and a history of motion sickness. It responds poorly to conventional antiemetics and better to anxiolytics, behavioral desensitization, and acupuncture.
Acute nausea occurs within the first 24 hours and is mediated mainly by serotonin (5-HT3) released by intestinal enterochromaffin cells — the basis for the effect of 5-HT3 antagonists such as ondansetron. Delayed nausea occurs between 24 hours and 5 days after chemotherapy, mediated by substance P and the NK1 receptor — which is why NK1 antagonists such as aprepitant are essential for highly emetogenic protocols. Distinguishing the phases is fundamental to choosing the right antiemetic.
Tumor-Related Hypercalcemia and Bowel Obstruction: Oncologic Emergencies
Tumor-related hypercalcemia is one of the most common metabolic complications in oncology patients, especially in multiple myeloma, bone metastases, and PTHrP-producing solid tumors. Nausea, vomiting, polyuria, polydipsia, constipation, mental confusion, and muscle weakness are the classic manifestations — the "bones, stones, groans, moans" mnemonic. Severe hypercalcemia (Ca > 14 mg/dL) is an emergency: vigorous IV hydration, bisphosphonates, and denosumab are the cornerstone of treatment.
Tumor-related bowel obstruction — from intraluminal mass, peritoneal carcinomatosis, or extrinsic compression — causes persistent nausea and vomiting unresponsive to conventional antiemetics. Warning signs include cessation of flatus and stool, progressive abdominal distention, and worsening with eating. Contrast-enhanced abdominal CT defines cause and extent. Management is multidisciplinary, involving the oncologist, surgeon, and palliative care — in advanced cases, octreotide and scopolamine reduce secretions and relieve symptoms.
Leptomeningeal Carcinomatosis: When Nausea and Headache Coexist
Leptomeningeal carcinomatosis — tumor dissemination through the meninges — occurs in 5-8% of patients with advanced solid cancer (breast, lung, melanoma) and at higher rates in lymphomas. Nausea with progressive headache, diplopia, neck stiffness, mental confusion, or focal neurologic signs in an oncology patient should raise this hypothesis. Magnetic resonance imaging with gadolinium and CSF analysis (cytology, protein, glucose) confirm the diagnosis.
Diagnosing leptomeningeal carcinomatosis carries significant prognostic and therapeutic impact — it changes staging, the systemic treatment plan, and the indication for craniospinal radiotherapy or intrathecal chemotherapy. The medical oncologist should be notified immediately on any suspicion, since early diagnosis can change the course. CINV from the chemotherapy cycle, although common, should never mask neurologic symptoms that demand independent investigation.
Treatment
CINV treatment is primarily preventive, with standardized protocols based on the regimen's emetogenic potential. International guidelines (ASCO, NCCN, MASCC) recommend risk-based antiemetic prophylaxis administered before the start of chemotherapy.
High Emetogenic Risk
Triple regimen: NK1 antagonist (aprepitant/fosaprepitant) + 5-HT3 antagonist (ondansetron/palonosetron) + dexamethasone. Quadruple regimen with olanzapine 10 mg for cisplatin-based regimens.
Moderate Emetogenic Risk
Doublet: 5-HT3 antagonist + dexamethasone. Consider NK1 antagonist for carboplatin-based regimens or with patient risk factors.
Low Emetogenic Risk
Single dose of dexamethasone or 5-HT3 antagonist before infusion. Rescue antiemetic available.
Anticipatory Nausea
Lorazepam the night before and the morning of the infusion. Cognitive behavioral therapy and systematic desensitization. Prevention is the best approach.
Acupuncture as Treatment
Acupuncture is recognized by the National Cancer Institute (NCI) and the National Comprehensive Cancer Network (NCCN) as complementary therapy for CINV. Stimulation of point PC-6 has consistent evidence as adjunctive to pharmacologic prophylaxis.
Proposed mechanisms include modulation of vagal afferents, regulation of emetic centers in the brainstem, modulation of serotonin and beta-endorphin release, and reduction of anticipatory anxiety. Acupuncture may be particularly useful for delayed and anticipatory nausea, which respond less well to conventional antiemetics.
Typical protocols include acupuncture or electroacupuncture sessions on the day of infusion and on subsequent days, combined with PC-6 acupressure (wristband) between sessions. Acupuncture does not replace pharmacologic prophylaxis, but it may reduce residual nausea and improve quality of life.
Prognosis
With modern antiemetic protocols, CINV can be controlled in 70-90% of patients. Response tends to be more effective for vomiting (60-80% complete control rate) than for nausea (40-60% complete control).
Inadequate CINV control in initial cycles increases the risk of anticipatory nausea and of worse control in subsequent cycles. For this reason, aggressive prophylaxis from the first cycle is fundamental.
CINV is a transient effect that ceases after chemotherapy ends. There are no long-term residual effects on the gastrointestinal tract once cancer treatment is completed.
Myths and Facts
Myth vs. Fact
Intense nausea means the chemotherapy is working
CINV intensity does not correlate with antitumor efficacy. Adequate nausea control does not reduce cancer treatment efficacy — on the contrary, it allows planned doses and intervals to be maintained.
All chemotherapy agents cause intense nausea
Emetogenic potential varies widely. Agents such as vincristine and bevacizumab cause minimal nausea (less than 10%), while cisplatin causes nausea in more than 90% without prophylaxis.
Antiemetics should only be taken when nausea is felt
Preventive prophylaxis — started before chemotherapy — is far more effective than rescue treatment once nausea is established. Waiting for symptoms to appear compromises control.
Cannabis is the best treatment for CINV
Although cannabinoids such as nabilone have some antiemetic efficacy, they are inferior to modern 5-HT3 and NK1 antagonists. They can serve as rescue therapy, but do not replace standard prophylaxis.
When to Seek Help
Mild nausea after chemotherapy is expected, but uncontrolled CINV requires intervention to avoid complications and maintain quality of life during treatment.
Frequently Asked Questions about Chemotherapy-Induced Nausea
Chemotherapy agents — especially platinums (cisplatin, carboplatin) and anthracyclines (doxorubicin) — trigger serotonin (5-HT3) release from intestinal enterochromaffin cells and directly activate the chemoreceptor trigger zone (CTZ) in the brainstem. They also stimulate NK1 receptors via substance P, producing delayed nausea. Intensity depends on the protocol's emetogenic potential, ranging from very high (cisplatin) to low (vincristine).
Acute nausea occurs within the first 24 hours after chemotherapy, mediated mainly by serotonin — it responds well to 5-HT3 antagonists such as ondansetron. Delayed nausea occurs from 24 hours to 5 days after infusion, mediated by substance P via NK1 receptors — and requires NK1 antagonists such as aprepitant for adequate control. The distinction is crucial: highly emetogenic protocols need coverage for both acute and delayed nausea, typically with ondansetron + aprepitant + dexamethasone.
Anticipatory nausea occurs before chemotherapy infusion — through classical conditioning, in which stimuli associated with the oncology environment (smells, sounds, colors) trigger the nausea response. It affects 20-30% of patients after cycles with inadequate control. It responds poorly to conventional antiemetics, but well to lorazepam, behavioral desensitization, and acupuncture. Prevention is the best strategy: aggressive nausea control in the first cycles prevents conditioning from developing.
Yes, with relevant evidence. The National Cancer Institute (NCI) and ASCO (American Society of Clinical Oncology) recognize acupuncture among the complementary options for CINV, especially anticipatory nausea and delayed nausea partially controlled by antiemetics. Point PC-6 (Neiguan) has the strongest support in the literature. Studies describe reduced frequency and intensity of nausea episodes and improved quality of life in some patients — as an adjunct, without replacing the pharmacologic prophylaxis prescribed by the oncologist. Treatment is delivered by an acupuncture physician.
The choice depends on the protocol's emetogenic potential. For high emetogenicity (cisplatin, carmustine): triple combination — NK1 antagonist (aprepitant or netupitant) + 5-HT3 antagonist (ondansetron) + dexamethasone. For moderate emetogenicity: ondansetron + dexamethasone ± aprepitant. For low emetogenicity: dexamethasone or prochlorperazine. PC-6 acupuncture may be added as a fourth agent in any protocol. The oncologist prescribes the individualized regimen.
Cold or room-temperature foods are better tolerated — hot foods have more odor, which is a powerful trigger for nausea. Ginger (in tea, crystallized, or as a supplement) has moderate evidence for reducing chemotherapy nausea. Small, frequent meals (every 2-3 hours) avoid both an empty stomach (which worsens nausea) and an overly full stomach. Simple carbohydrates, rice, toast, and banana are well tolerated. Avoid fatty, spicy, and highly aromatic foods on chemotherapy days.
It varies by patient and protocol. With adequate antiemetic prophylaxis and cycle-by-cycle adjustments, many patients achieve progressively better control. However, anticipatory nausea tends to worsen across cycles if untreated — conditioning intensifies with each negative experience. Communicating nausea intensity and duration to the oncology team at each cycle is essential, so prophylaxis can be adjusted proactively in subsequent cycles rather than waiting for worsening.
Cannabinoids — especially dronabinol (synthetic THC) and nabilone — have FDA approval for CINV refractory to other antiemetics. Evidence shows efficacy in refractory nausea and vomiting, with a side-effect profile (sedation, disorientation, altered perception) that limits use in older adults and patients with psychiatric comorbidities. In Brazil, medical cannabis can be prescribed by a physician in specific cases after individual assessment. It is not first-line treatment.
Yes. Persistent vomiting causes volume depletion and electrolyte imbalance (hypokalemia, hyponatremia, metabolic alkalosis) that can compromise the safety of the next chemotherapy cycle, delay treatment, and worsen general status. Warning signs of dehydration: dizziness on standing, dry mouth, very dark urine or no urine for more than 8 hours, mental confusion, and extreme fatigue. These symptoms require urgent IV hydration — contact the oncology team immediately.
Contact your oncology team if: vomiting persists more than 24 hours despite prescribed antiemetics; you cannot take fluids or oral medications for more than 12 hours; you have lost more than 2 kg in one week; you show signs of dehydration (dizziness, dark urine); nausea comes with fever (suspected febrile neutropenia); or nausea intensity has increased significantly compared to previous cycles. Proactive treatment adjustment is always preferable to hospitalization for complications.
Related Reading
Deepen your knowledge with related articles